Interventions for the management of fatigue in adults with a primary brain tumour

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Day, Julia ^a   Yust Katz, Shlomit ^b   Cachia, David ^c   Wefel, Jeffrey ^d   Katz, Lior H ^d   Tremont, Ivo ^d   Bulbeck, Helen ^e   Armstrong, Terri ^d   Rooney, Alasdair G ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b RABIN MEDICAL CENTER   (Israel)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Brainstrust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; WAKEFULNESS PROMOTING AGENT;

ADULT; BRAIN TUMOR; COGNITION; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; LOSS OF APPETITE; MOOD; NERVOUSNESS; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SKIN TINGLING; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPLICATION;

ADULT; BENZHYDRYL COMPOUNDS; BRAIN NEOPLASMS; FATIGUE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WAKEFULNESS-PROMOTING AGENTS;

EID: 84963646142     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011376.pub2     Document Type: Review

References (61)

1. Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology 2013;15(10):1420-8.
2. Butler JM, Case LM, Atkins J, Frizzell B, Sanders G, Griffin P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. International Journal of Radiation Oncology *Biology *Physics 2007;69(5):1496-501.
3. Gehring K, Sitskoorn MM, Gundy CM, Sikkes SAM, Klein M, Postma TJ, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. Journal of Clinical Oncology 2009;27(22):3712-22.
4. Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, et al. A randomised trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. Journal of Neuro-Oncology 2012;107(1):165-74. [DOI: 10.1007/s11060-011-0723-1]
5. Kaleita TA, Wellisch DK, Graham CA, Steh B, Nghiemphu P, Ford JM, et al. Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. Journal of Clinical Oncology 2006;24(18S):1503.
6. Lee E, Muzikansky A, Kesari S, Wong E, Fadul C, Reardon DA, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology 2014;16(Suppl 5):v206.
7. Locke DEC, Cerhan JH, Wu W, Malec JF, Clark MM, Rummans TA, et al. Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: a pilot study. Journal of Supportive Oncology 2008;6(8):383-91.
8. Shaw EG, Rosdhal R, D'Agostino RB, Lovato J, Naughton MJ, Robbins ME, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. Journal of Clinical Oncology 2006;24(9):1415-20.
9. Page BR, Shaw EG, Lu L, Bryant D, Grisell D, Lesser GJ, et al. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro-Oncology 2015;0:1-9.
10. Armodafinil in Reducing Cancer-Related Fatigue in Patients with High Grade Glioma. Ongoing study 2013.
11. Arlt W, Hove U, Müller B, Reincke M, Berwiler U, Schwab F, et al. Frequency and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors or primary brain tumours. Neurology 1997;49(2):498-506. [PUBMED: 9270585]
12. Armstrong TS, Mendoza T, Gring I, Coco C, Cohen MZ, Eriksen L, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumour Module (MDASI-BT). Journal of Neuro-Oncology 2006;80(1):27-35. [PUBMED: 16598415]
13. Armstrong TS, Cron SG, Boloanos EV, Gilber MR, Kang DH. Risk factors for fatigue severity in primary brain tumour patients. Cancer 2010;116(11):2707-15. [DOI: 10.1002/cncr.25018]
14. Armstrong TS, Gilbert MR. Practical strategies for management of fatigue and sleep disorders in people with brain tumors. Neuro-Oncology 2012;14(Suppl 4):iv65-iv72. [DOI: 10.1093/neuonc/nos210]
15. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York: Guildford Press, 1979.
16. Bowe JE. Fatigue, brain, behavior, and immunity: summary of the 2012 Named Series on fatigue. Behavior and Immunity 2012;26(8):1220-3. [10.1016/j.bbi.2012.08.009]
17. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. Journal of Clinical Oncology 1993;11(3):570-9. [PUBMED: 8445433 ]
18. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD006145.pub2]
19. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323(7305):157-62. [DOI: 10.1136/bmj.323.7305.157]
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
21. Dimeo FC. Effects of exercise on cancer-related fatigue. Cancer 2001;92(6 Suppl):1689-93.
22. Drappatz J, Schiff D, Kesari S, Norden AD, Wen P. Medical management of brain tumour patients. Radiotherapy Oncology 2007;100(1):131-6. [DOI: 10.1016/j.ncl.2007.07.015]
23. Fox SW, Lyon D, Ferace E. Symptom clusters in patients with high-grade glioma. Journal of Nursing Scholarship 2007;39(1):61-7. [PUBMED: 17393967]
24. Glaus A. Fatigue in patients with cancer. Analysis and assessment. Recent Results Cancer Research 1998;I44(I-XI):1-172. [PUBMED: 9551500]
25. Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006953.pub2]
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Hinds PS, Hockenberry MJ, Gattuso JS, Srivastava DK, Tong X, Jones H, et al. Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Cancer 2007;110(10):2321-30. [PUBMED: 17926333]
28. Holley SK. Evaluating patient distress from cancer-related fatigue: an instrument development study. Oncology Nursing Forum 2000;27(9):1425-31. [PUBMED: 11058974]
29. International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. CFR & ICH Guidelines 1997;1(1):19063-2043.
30. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR. Assessment of cancer-related fatigue: Implications for clinical diagnosis and treatment. The Oncologist 2007;12(Suppl 1):11-21. [PUBMED: 17573452]
31. Katz LH, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD008516.pub2]
32. Kim BR, Chun MH, Han EY, Kim D-K. Fatigue assessment and rehabilitation outcomes in patients with brain tumours. Supportive Care in Cancer 2012;20(4):805-12. [DOI: 10.1007/s00520-011-1153-5]
33. Kvale EA, Murthy R, Taylor R, Lee JY, Nabors LB. Distress and quality of life in primary high-grade brain tumour patients. Supportive Care in Cancer 2009;17(7):793-9. [DOI: 10.1007/s00520-008-0551-9]
34. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. Journal of the National Cancer Institute. Monographs 2004;32:40-50.
35. Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncology Nursing Forum 1999;26(5):921-5. [PUBMED: 10382191]
36. Lu Y, Yu W, Wang X. Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation. CNS Drugs 2009;23(4):351-9. [PUBMED: 19374462]
37. Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella C, Pace A, et al. Outcome and tolerability of topiramate in brain tumour associated epilepsy. Journal of Neuro-Oncology 2008;86(1):61-70. [PUBMED: 17598071 ]
38. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85(5):1186-96. [PUBMED: 10091805 ]
39. Miaskowski C, Lee K, Dunn L, Dodd M, Aouizerat BE, West C, et al. Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. Cancer Nursing 2011;34(4):255-68. [DOI: 10.1097/NCC.0b013e3181f65d9b]
40. Minton O, Richardson A, Sharpe M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006704.pub2]
41. Minton O, Berger A, Barsevick A, Cramp F, Goedendorp M, Mitchell SA, et al. Cancer-related fatigue and its impact on functioning. Cancer 2013;119(S11):2124-30.
42. Molassiotis A, Wilson B, Brunton L, Chaudhary H, Gattamaneni R, McBain C. Symptom experience in patients with primary brain tumours: a longitudinal exploratory study. European Journal of Oncology Nursing 2010;14(5):410-6. [DOI: 10.1016/j.ejon.2010.03.001]
43. National Comprehensive Cancer Network (NCCN). Cancer-related fatigue. NCCN Clinical Practice Guidelines in Oncology 2014; Vol. Version 1.2014.
44. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumour patients: the relative contribution of depression, fatigue, emotional distress and existential issues. Journal of Neuro-Oncology 2002;57(1):41-9. [PUBMED: 12125966 ]
45. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Sale: psychometric evaluation in women with breast cancer. Oncology Nursing Forum 1998;25(4):677-87. [PUBMED: 9599351 ]
46. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
47. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Quality of Life Research 1993;2(2):129-40.
48. Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic review of observational studies. Journal of the National Cancer Institute 2011;103(1):61-76. [DOI: 10.1093/jnci/djq458]
49. Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Matteson S, Rakita D, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002;10(4):329-36. [PUBMED: 12029433]
50. Salo J, Neimela A, Joukamaa M, Koivukangas J. Effect of brain tumour laterality on patients' perceived quality of life. Journal of Neurology Neurosurgery and Psychiatry 2002;72(3):373-7. [PUBMED: 11861699]
51. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon D, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro-oncology 2014;0:1-17.
52. Servaes P, Gielissen M, Verhagen S, Bleijenberg G. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psycho-oncology 2007;16(9):787-95. [PUBMED: 17086555]
53. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the Multidimensional Fatigue Symptoms Inventory - Short Form. Journal of Pain and Symptom Management 2004;27(1):14-23. [DOI: 10.1016/j.jpainsymman.2003.06.003]
54. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Annals of Oncology 2000;11(8):971-5. [PUBMED: 11038033]
55. Struik K, Klein M, Heimans JJ, Gielissen MF, Bleijenberg G, Taphoorn MJ, et al. Fatigue in low-grade glioma. Journal of Neuro-Oncology 2009;92(1):73-8. [DOI: 10.1007/s11060-008-9738-7]
56. Taphoorn MJB, Heimans JJ, van der Veen EA, Karim ABMF. Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy. Journal of Neuro-Oncology 1995;25(2):97-102. [PUBMED: 8543975]
57. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. Journal of Attention Disorders 2002;6(Suppl 1):S31-43. [PUBMED: 12685517]
58. The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL): Position Paper from the World Health Organization. Social Science and Medicine 1995;41(10):1403-9. [PUBMED: 8560308]
59. Winningham ML. How exercise mitigates fatigue: implications for people receiving cancer therapy. In: Carroll-Johnson RM editor(s). The Biotherapy of Cancer V. Pittsburgh: Oncology Nursing Press, 1992:16-21.
60. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management 1997;13(2):63-74. [PUBMED: 9095563]
61. Young JW, Greyer MA. Action of modafinil-increased motivation via the dopamine transporter inhibition and D1 receptors?. Biological Psychiatry 2010;67(8):784-7. [DOI: 10.1016/j.biopsych.2009.12.015]